

PERSONAL INFORMATION Ilaria Vicenti



✉ ilaria.vicenti@unicamillus.org
 ⓘ <http://www.unicamillus.org/professors>

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input checked="" type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

BRIEF PRESENTATION

Professor Ilaria Vicenti PhD is specialized in the virology field, particularly antiviral drug resistance and evaluation of viral persistence and viral evolution. She has been working on HIV drug resistance for more than 15 years taking part many international initiatives and collaborating with pharmaceutical companies. In the last ten years she has worked in antiviral drug discovery and development, expanding his area of interest to flaviviruses and more recently to SARS-COV-2 new coronavirus where she has started to study the impact of neutralizing antibody response in patients previously infected and/or vaccinated.

WORK EXPERIENCE

14/07/2025-present	Associate Professor UniCamillus —International Medical University in Rome, SSD MEDS-03A
01/07/2020-30/06/2025	Junior researcher (RTD-A) at the Department of Medical Biotechnologies University of Siena, Italy <ul style="list-style-type: none"> Since 2020-2021 Teaching Microbiology [cod. 2012304, 3 CFU (30 hours)], for Biomedical Laboratory Technicians degree [MED011] (L. D.M. 270/2004) Research in molecular diagnostics applied to human viral infections, antiviral drugs discovery and antiviral drug resistance. Tutor professor for the Department of Medical Biotechnologies since 2023. Delegate for Third Mission for the Department of Medical Biotechnology since May 2023. Tutor and Thesis supervisor: Supervisor for Dr. Camilla Biba (Matricola 098722, a.a. 2020-2021, CLM Medical Biotechnologies) Second Supervisor for Dr. Niccolò Bartolini (Matricola 104200, a.a. 2021-2022, CLM Medical Biotechnologies), Dr. Chiara Paletti (Matricola 108698, anno accademico 2021-2022, CLM Medical Biotechnologies), Dr Antonio Bordoni Giulio (Matricola 133786, anno accademico 2023-2024)
01/03/2014-28/02/2020	Research fellow in Microbiology and Virology University of Siena, Department of Medical Biotechnologies, Italy <ul style="list-style-type: none"> Subject of Project (2018-2020): "Valutazione della risposta virologica al trattamento antivirale e della qualità di vita in pazienti con coinfezione da HIV e HCV". Subject of Project (2014-2018): Phenotypic analysis of the antiviral activity of potential nucleocapsid inhibitors against HIV variants showing resistance to current antiretrovirals, in the context of THINPAD project – Targeting the HIV-1 Nucleocapsid Protein to flight Antiretroviral Drug Resistance
01/12/2012-01/06/2013	Scientific Referent University of Siena, Department of Medical Biotechnologies, Italy <ul style="list-style-type: none"> Scientific Referent in the context of ARCA project, commitment of work Informa srl. The ARCA database, is a collection of clinical and virological data, including data of early 26.000 patients coming from 10 years of research in the HIV field. The ARCA database takes advantage from the collaboration of early one hundred Italian centre for the HIV healthcare. https://www.hivarca.net/
01/09/2011-30/10/2012	Research Associate

	Novartis Research Centre, Unit Viral Serology
	<ul style="list-style-type: none"> Development of microneutralization assays based on the use on viral pseudoparticles to screen sera of vaccinated mice and/or human.

EDUCATION AND TRAINING

26/11/2024	Obtain the National Scientific qualification as associate in the Italian higher education system, in the call 2023/2025 (Ministerial Decree n. 1796/2023) for the disciplinary field of 06/N1 - SCIENZE DELLE PROFESSIONI SANITARIE E DELLE TECNOLOGIE MEDICHE APPLICATE. The National qualification is valid until 19/11/2035
20/09/2024	Obtain the National Scientific qualification as associate in the Italian higher education system, in the call 2023/2025 (Ministerial Decree n. 1796/2023) for the disciplinary field of 05/I2 - Microbiology. The National qualification is valid until 25/06/2035
28/05/2023	Obtain the National Scientific qualification as associate in the Italian higher education system, in the call 2021/2023 (Ministerial Decree n. 553/2021 and 589/2021) for the disciplinary field of 06/A3 - Microbiology and clinical microbiology. The National qualification is valid until 28/05/2033

01/11/2017 – 06/09/2021	Master of Sciences in Microbiology and Virology (full marks with laude) Specializzazione in Microbiologia e Virologia. University of Siena, Italy. Thesis title: "External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy"
01/09/2005 – 23/11/2009	Europaeus Ph.D. (XXI cycle) European Doctorate Research School in Biotechnology at the University of Siena. During the PhD was attended for 3-months the German National Reference Center for Retroviruses at the Institute for Clinical and Molecular Virology of the University Hospital Erlangen Nuremberg. The purpose of the internship was the training in the management and procedures of a laboratory with a security level 3 and the generation of recombinant viruses. - Clinical implication of HIV-1 genetic variability". Experimental work was carried out in the Virology laboratory
01/09/2003 – 21/07/2005	Master's degree in biotechnologies for Human Health (LS-9) (full marks with laude) University of Siena, Italy Degree title: "Evaluation of Enfuvirtide resistance onset in HIV-positive patients during the antiretroviral treatment"

PERSONAL SKILLS

Mother tongue(s)	Italian
Other language(s)	English, excellent; French, good

Job-related skills	<ul style="list-style-type: none"> Investigator in different HIV, SARS-CoV-2 and flaviviruses related research projects together with other academic scientists from Italy and abroad and with pharmaceutical companies. Relevant grants: <ul style="list-style-type: none"> <u>Fellowship Program Gilead 2012</u>. The role of the viral reservoir and residual viremia in patients switched to raltegravir plus 2 NRTIs after virological suppression. <u>THINPAD (FP7-HEALTH-2013-INNOVATION-2)</u>: "Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance", 2013. <u>Fellowship Program Gilead 2015</u>. HBV DNA distribution in PBMC and plasma from HBV inactive carriers and patients with occult HBV infection (OBI). <u>Tuscany Region FAS-Salute</u>: "UNAVIR: a novel strategy to combat multiple viral infections with one antiviral". 2016. <u>Fellowship Program Gilead 2017</u>. Changes in total and integrated HIV-1 DNA following treatment deintensification. <u>Tuscany Region POR-FESR 2014-2020</u> "PANVIR.NET: preclinical development of innovative PANVIRal antivirals in a specialized regional Network". 2018. <u>CARE (H2020) Research and Innovation action: H2020-SC1-2018-Single-Stage-RTD - SC1-BHC-21-2018</u>: "Common Action against HIV/TB/HCV across the Regions of Europe". Grant agreement ID: 825673. 2019. <u>PRIN 2017</u>: "ORIGINALE CHEMIAE in Antiviral Strategy - Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad Spectrum Antiviral Strategy". Prot. 2017BMK8JR. <u>AIFA 2017 Call for Independent Drug Research</u>: "OPTIMA - Strategies to Contain HIV Drug-Resistance Emergence in Virologically Suppressed Patients Requiring Antiretroviral Therapy Optimization: Unraveling the Mutational Burden in PBMCs". AIFA Code TRS-2018-00001336. 2019. <u>Bando Ricerca Salute 2018. TUSCAVIR</u>: "Tuscany Antiviral Research Network" <u>Tuscany Region COVID-19, 2020-2021. APICE</u> (Antibodies and Peptides Inhibiting Coronavirus Entry).
--------------------	---

	<ul style="list-style-type: none"> ▪ Intesa Sanpaolo, 2021. Fermare l'infezione da coronavirus: sviluppo di inibitori della proteasi di SARSCoV-2 e Proteine omologhe e di composti multifunzionali contro la replicazione virale e i meccanismi di ingresso. ID progetto: B/2020/0113. ▪ HORIZON-HLTH-2021-CORONA-01, HORIZON-RIA. EuCARE: European Cohorts of Patients and Schools to Advance Response to Epidemics. 2021-2024 ▪ PRIN 2020 (Ministry of University and Research, Italy): "Genomic epidemiology and phylogenesis of SARS-CoV-2 in Italy: identification and characterization of circulating variants of clinical and public health relevance"; 2020; Prof Vicenti Ilaria Unit Head. ▪ Participant to the NextGeneration EU-MUR PNRR project, funded by European Community. The extended partnership (PE13) focus on Emerging Infectious Disease (Project no. PE00000007, INF-ACT, INF-ACT "One Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases") ▪ RIPREI project "Rete Italiana per la sorveglianza virologica, il monitoraggio immunologico, la formazione e la ricerca in Preparazione alla gestione delle Emergenze Infettive" funded by Istituto Superiore di Sanità (code RIPREI2023_ad5d6fa48de5). Title: "A comprehensive toolbox for timely phenotypic characterization of novel SARS-CoV-2 variants (PHENO-BOX)". Prof Vicenti Ilaria Principal Investigator
--	--

Digital skills	Advanced use of the Windows operating system. Excellent knowledge of the main office suites. Advanced knowledge of DNA/protein analysis software packages (DNASTAR, Vector NTI, Mega, BioEdit). Good knowledge of statistical packages (SSPS, Statistica, Sigmaplot). Continuous use of web resources such as medical education, scientific databases (e. g. PubMed, GenBank, NCBI, LANL).
----------------	--

Laboratory skills	<ul style="list-style-type: none"> • RNA/DNA extraction, electrophoresis on agarose and polyacrylamide gels. • Qualitative PCR on DNA/RNA viruses and human target (i.e HLA, SNPs). • Quantitative Real Time PCR on DNA/RNA viruses and human target. • Digital droplet PCR (ddPCR) to quantify HIV and SARS-CoV-2 in clinical samples • DNA sequencing (capillary sequencing and full-length NGS). • Base knowledge on cellular biology techniques (culture of murine and human cell lines, transfections). • DNA cloning in <i>E. coli</i>. • Development of systems for the drug resistance therapy virologic monitoring. • Analysis of HIV antiretroviral drug resistances. • Qualitative diagnosis of human viruses (HSV1, HSV2, HSV6, HSV7, HSV8, CMV, EBV, ADV, VZ, JC, B19, HIV1, HIV2). • Generation of high-titred HIV cell culture supernatants. • Infection-based determination of phenotypic drug resistance and viral replicative capacity using recombinant HIV-1 viruses and high titrated viral isolates (HIV-1, flaviviruses). • Serologic analysis: ELISA, test of inhibition of hemagglutination, microneutralization assays and pseudotype neutralization. • Cell-based assays for the determination of antiviral (drugs) and neutralization (antibodies) activity against flaviviruses and SARS-CoV-2
-------------------	---

Researcher Identification	<p>ORCID: 0000-0002-4306-2960 Scopus ID: 13905317900 Researcher ID: AAP-9663-2020</p> <ul style="list-style-type: none"> ▪ 89 peer-reviewed publications indexed in PubMed https://www.ncbi.nlm.nih.gov/myncbi/ilaria.vicenti.2/bibliography/public ▪ H index: 20 (Scopus)
Publications	<ol style="list-style-type: none"> 1. Amodeo, D., Marchi, S., Fiaschi, L. et al. Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm). <i>Applied and environmental microbiology</i>. 2025; e0040325. Advance online publication. https://doi.org/10.1128/aem.00403-25 2. Giammarino F, Paletti C, Bartolini N, et al. Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro. <i>Antiviral Res</i>. Published online April 18, 2025. doi:10.1016/j.antiviral.2025.106157 3. Bergna A, Lai A, Sagradi F, et al. Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era. <i>J Med Virol</i>. 2025;97(2):e70215. doi:10.1002/jmv.70215 4. Rossi S, Deidda G, Fiaschi L, et al. Synthesis and biological investigation of peptidomimetic SARS-CoV-2 main protease inhibitors bearing quinoline-based heterocycles at P₃. <i>Arch Pharm (Weinheim)</i>. 2025;358(1):e2400812. doi:10.1002/ardp.202400812

5. Biba, C., Fiaschi, L., Varasi, I., Paletti, C., Bartolini, N., Zazzi, M., Vicenti, I.* & Saladini, F. (2024). A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations. *Viruses*, 16(9), 1465. <https://doi.org/10.3390/v16091465> Armenia D, Carioti L, Micheli V, et al. Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy. *Viruses*. 2024;16(9):1422. Published 2024 Sep 6. doi:10.3390/v16091422
6. Bonomini A, Felicetti T, Pacetti M, Bertagnin C, Coletti A, Giammarino F, De Angelis M, Poggialini F, Macchiarulo A, Sabatini S, Mercorelli B, Nencioni L, Vicenti I, Dreassi E, Cecchetti V, Tabarrini O, Loregian A, Massari S. Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization. *Eur J Med Chem*. 2024 Nov 5;277:116737. doi: 10.1016/j.ejmech.2024.116737. Epub 2024 Aug 3. PubMed PMID: 39153334.
7. Di Teodoro G, PirkI M, Incardona F, Vicenti I, Sönnnerborg A, Kaiser R, Palagi L, Zazzi M, Lengauer T. Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1. *Bioinformatics*. 2024 Jun 3;40(6). doi: 10.1093/bioinformatics/btae327. PubMed PMID: 38775719; PubMed Central PMCID: PMC11153833.
8. Milano G, Marchi S, Vicenti I, Biba C, Fiaschi L, Trombetta CM, Lazzeri G, Montomoli E, Manini I. SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season. *J Prev Med Hyg*. 2024 Mar;65(1):E11-E16. doi: 10.15167/2421-4248/jpmh2024.65.1.3179. eCollection 2024 Mar. PubMed PMID: 38706768; PubMed Central PMCID: PMC11066830.
9. Cesarini S, Vicenti I*, Poggialini F, Filippi S, Mancin E, Fiaschi L, De Marchi E, Giammarino F, Vagaggini C, Bizzarri BM, Saladino R, Dreassi E, Zazzi M, Botta L. Serendipitous Identification of Azine Anticancer Agents Using a Privileged Scaffold Morphing Strategy. *Molecules*. 2024 Mar 24;29(7). doi: 10.3390/molecules29071452. PubMed PMID: 38611732; PubMed Central PMCID: PMC11013010.
10. Pacetti M, Pismataro MC, Felicetti T, Giammarino F, Bonomini A, Tiecco M, Bertagnin C, Barreca ML, Germani R, Cecchetti V, Vicenti I, Tabarrini O, Zazzi M, Loregian A, Massari S. Switching the three-component Biginelli-like reaction conditions for the regio iver synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines. *Org Biomol Chem*. 2024 Jan 24;22(4):767-783. doi: 10.1039/d3ob01861j. PubMed PMID: 38167738.
11. Fiaschi L, Biba C, Varasi I, Bartolini N, Paletti C, Giammarino F, Saladini F, Zazzi M, Vicenti I*. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. *Viruses*. 2024 Jan 23;16(2). doi: 10.3390/v16020168. PubMed PMID: 38399944; PubMed Central PMCID: PMC10892871.
12. Bergna A, Lai A, Ventura CD, Bruzzone B, Weisz A, d'Avenia M, Testa S, Torti C, Sagnelli C, Menchise A, Brindicci G, Francisci D, Vicenti I, Clementi N, Callegaro A, Rullo EV, Caucci S, De Pace V, Orsi A, Brusa S, Greco F, Letizia V, Vaccaro E, Franci G, Rizzo F, Sagradi F, Lanfranchi L, Coppola N, Saracino A, Sampaolo M, Ronchiadin S, Galli M, Riva A, Zehender G. Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021. *J Med Virol*. 2023 Nov;95(11):e29193. doi: 10.1002/jmv.29193. PubMed PMID: 37927140.
13. Varasi I, Lai A, Fiaschi L, Bergna A, Gatti A, Caimi B, Biba C, Della Ventura C, Balotta C, Riva A, Zehender G, Zazzi M, Vicenti I*. Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination. *J Infect*. 2023 Sep;87(3):270-272. doi: 10.1016/j.jinf.2023.06.019. Epub 2023 Jun 30. PubMed PMID: 37394012.
14. Grazia Martina M, Giammarino F, Vicenti I, Groaz E, Rozenski J, Incerti M, Sannio F, Docquier JD, Zazzi M, Radi M. Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties. *ChemMedChem*. 2023 Aug 15;18(16):e202300200. doi: 10.1002/cmcd.202300200. Epub 2023 Jun 2. PubMed PMID: 37221137.
15. Sanna C, D'Abrosca B, Fiorentino A, Giammarino F, Vicenti I, Corona A, Caredda A, Tramontano E, Esposito F. HIV-1 Integrase Inhibition Activity by Spiroketal Derived from *Plagius flosculosus*, an Endemic Plant of Sardinia (Italy) and Corsica (France). *Pharmaceuticals (Basel)*. 2023 Aug 8;16(8). doi: 10.3390/ph16081118. PubMed PMID: 37631033; PubMed Central PMCID: PMC10457970.
16. Vicenti I, Basso M, Pirola N, Bragato B, Rossi MC, Giobbia M, Pascoli S, Vinci A, Caputo S, Varasi I, Biba C, Fiaschi L, Zazzi M, Parisi SG. SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy. *Vaccines (Basel)*. 2023 Apr 20;11(4). doi: 10.3390/vaccines11040871. PubMed PMID: 37112782; PubMed Central PMCID: PMC10144758.
17. Del Rosario García-Lozano M, Dragoni F, Gallego P, Mazzotta S, López-Gómez A, Boccuto A, Martínez-Cortés C, Rodríguez-Martínez A, Pérez-Sánchez H, Manuel Vega-Pérez J, Antonio Del Campo J, Vicenti I*, Vega-Holm M, Iglesias-Guerra F. Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses. *Bioorg Chem*. 2023 Apr;133:106408. doi: 10.1016/j.bioorg.2023.106408. Epub 2023 Feb 4. PubMed PMID: 36801791.
18. Salvo PF, Farinacci D, Ciccullo A, Borghi V, Rusconi S, Saracino A, Gennari W, Bruzzone B, Vicenti I, Callegaro A, Di Biagio A, Zazzi M, Di Giambenedetto S, Borghetti A. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. *Viruses*. 2023 Mar 16;15(3). doi: 10.3390/v15030762. PubMed PMID: 36992471; PubMed Central PMCID: PMC10059835.
19. Marchi S, Dragoni F, Boccuto A, Idoko OT, Zazzi M, Sow S, Diallo A, Viviani S, Montomoli E, Vicenti I, Trombetta CM. Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. *Acta Trop*. 2023 Jan;237:106736. doi: 10.1016/j.actatropica.2022.106736. Epub 2022 Oct 29. PubMed PMID: 36374844.
20. Cesarini S, Vicenti I, Poggialini F, Secchi M, Giammarino F, Varasi I, Lodola C, Zazzi M, Dreassi E, Maga G, Botta L, Saladino R. Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity. *Molecules*. 2022 Dec 12;27(24). doi: 10.3390/molecules27248829. PubMed PMID: 36557962; PubMed Central PMCID: PMC9782877.
21. Dragoni F, Rossetti B, Lombardi F, Spertilli Raffaelli C, Bartolini N, Giammarino F, Moschese D, Di Giambenedetto S, Fabbiani M, De Luca A, Vicenti I, Zazzi M, Saladini F. Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy. *J Acquir Immune Defic Syndr*. 2022 Dec 1;91(4):381-389. doi: 10.1097/QAI.0000000000003073. PubMed PMID: 35969477.
22. Lai A, Bergna A, Della Ventura C, Menzo S, Bruzzone B, Sagradi F, Ceccherini-Silberstein F, Weisz A, Clementi N, Brindicci G, Vicenti I, Sasset L, Caucci S, Corvaro B, Ippoliti S, Acciarri C, De Pace V, Lanfranchi L, Bellocchi MC,

- Giurato G, Ferrarese R, Lagioia A, Francisci D, Colombo ML, Lazzarin S, Ogliastrro M, Cappelletti MR, Iannetta M, Rizzo F, Torti C, Fumi M, d'Avenia M, Brusa S, Greco F, Menchise A, Letizia V, Vaccaro E, Santoro CR, Fraccalvieri C, Testa S, Carioti L, Rocco T, Saracino A, Cattelan A, Clementi M, Sarmati L, Riva A, Galli M, Antinori S, Zehender G, Sars-CoV-Italian Research Enterprise-Scire Collaborative Group. Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April-December 2021 in Italy. *Viruses*. 2022 Nov 12;14(11). doi: 10.3390/v14112508. PubMed PMID: 36423117; PubMed Central PMCID: PMC9699621.
23. Stella G, Volpicelli L, Carlo DD, Vicenti I, Celani L, Maggiolo F, Callegaro AP, Gennari W, Francisci D, Lombardi F, Piermatteo L, Bezenchek A, Micheli V, Rossetti B, Santoro MM. Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV. *Int J Antimicrob Agents*. 2022 Sep;60(3):106636. doi: 10.1016/j.ijantimicag.2022.106636. Epub 2022 Jul 9. PubMed PMID: 35820534.
 24. Luddi A, Luongo FP, Dragoni F, Fiaschi L, Vicenti I, Lupetti P, Gentile M, Paccagnini E, Haxhiu A, Ponchia R, Governini L, Zazzi M, Piomboni P. Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm. *Cells*. 2022 Aug 24;11(17). doi: 10.3390/cells11172631. PubMed PMID: 36078041; PubMed Central PMCID: PMC9455059.
 25. Parisi SG, Mengoli C, Basso M, Vicenti I, Gatti F, Scaggiante R, Fiaschi L, Giammarino F, Iannetta M, Malagnino V, Zago D, Dragoni F, Zazzi M. Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses. *Vaccines (Basel)*. 2022 Aug 2;10(8). doi: 10.3390/vaccines10081237. PubMed PMID: 36016125; PubMed Central PMCID: PMC9416151.
 26. Gidari A, Sabbatini S, Schiaroli E, Bastianelli S, Pierucci S, Busti C, Comez L, Libera V, Macchiarulo A, Paciaroni A, Vicenti I, Zazzi M, Francisci D. The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro. *Microorganisms*. 2022 Jul 21;10(7). doi: 10.3390/microorganisms10071475. PubMed PMID: 35889194; PubMed Central PMCID: PMC9323947.
 27. Dragoni F, Schiaroli E, Micheli V, Fiaschi L, Lai A, Zehender G, Rossetti B, Gismondo MR, Francisci D, Zazzi M, Vicenti I*. Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies. *Clin Microbiol Infect*. 2022 Jul;28(7):1037-1039. doi: 10.1016/j.cmi.2022.03.005. Epub 2022 Mar 15. PubMed PMID: 35304279; PubMed Central PMCID: PMC8923034.
 28. Schiaroli E, De Socio GV, Gidari A, Malincame L, Benedetti S, Lanzani A, Bastianelli S, Pierucci S, Busti C, Fagotti B, Vicenti I, Zazzi M, Francisci D. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria. *Mediterr J Hematol Infect Dis*. 2022;14(1):e2022050. doi: 10.4084/MJHID.2022.050. eCollection 2022. PubMed PMID: 35865399; PubMed Central PMCID: PMC9266464.
 29. Fiaschi L, Dragoni F, Schiaroli E, Bergna A, Rossetti B, Giammarino F, Biba C, Gidari A, Lai A, Nencioni C, Francisci D, Zazzi M, Vicenti I*. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. *Viruses*. 2022 Jun 23;14(7). doi: 10.3390/v14071374. PubMed PMID: 35891355; PubMed Central PMCID: PMC9321742.
 30. Luongo FP, Dragoni F, Boccuto A, Paccagnini E, Gentile M, Canosi T, Morgante G, Luddi A, Zazzi M, Vicenti I, Piomboni P. SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility. *Cells*. 2022 Apr 23;11(9). doi: 10.3390/cells11091431. PubMed PMID: 35563737; PubMed Central PMCID: PMC9105548.
 31. Vicenti I, Basso M, Dragoni F, Gatti F, Scaggiante R, Fiaschi L, Parisi SG, Zazzi M. Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. *Vaccines (Basel)*. 2022 Apr 9;10(4). doi: 10.3390/vaccines10040580. PubMed PMID: 35455329; PubMed Central PMCID: PMC9025891.
 32. Lai A, Bergna A, Toppo S, Morganti M, Menzo S, Ghisetti V, Bruzzone B, Codeluppi M, Fiore V, Rullo EV, Antonelli G, Sarmati L, Brindicci G, Callegaro A, Sagnelli C, Francisci D, Vicenti I, Miola A, Tonon G, Cirillo D, Menozzi I, Caucci S, Cerutti F, Orsi A, Schiavo R, Babudieri S, Nunnari G, Mastroianni CM, Andreoni M, Monno L, Guarneri D, Coppola N, Crisanti A, Galli M, Zehender G. Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. *Sci Rep*. 2022 Apr 6;12(1):5736. doi: 10.1038/s41598-022-09738-0. PubMed PMID: 35388091; PubMed Central PMCID: PMC8986836.
 33. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, Basso M, Dragoni F, Parisi SG, Zazzi M. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. *Infection*. 2022 Apr;50(2):541-543. doi: 10.1007/s15010-021-01680-z. Epub 2021 Aug 3. PubMed PMID: 34342854; PubMed Central PMCID: PMC8329626.
 34. Vicenti I*, Dragoni F, Giannini A, Casabianca A, Lombardi F, Di Sante L, Turriziani O, Racca S, Paolucci S, Lai A, Bon I, Abbate I, Rozera G, Belmonti S, Scutari R, Alteri C, Saladini F, Zazzi M. External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. *Sci Rep*. 2022 Feb 28;12(1):3291. doi: 10.1038/s41598-022-07196-2. PubMed PMID: 35228581; PubMed Central PMCID: PMC8885833.
 35. Boccuto A, Dragoni F, Bergna A, Ventura CD, Giammarino F, Saladini F, Pezzati L, Zehender G, Zazzi M, Vicenti I, Lai A. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals. *J Infect*. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.08.005. Epub 2021 Aug 8. PubMed PMID: 34371077; PubMed Central PMCID: PMC8349389.
 36. Cirri D, Marzo T, Tolbatov I, Marrone A, Saladini F, Vicenti I, Dragoni F, Boccuto A, Messori L. In Vitro Anti-SARS-CoV-2 Activity of ed Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study. *Biomolecules*. 2021 Dec 10;11(12). doi: 10.3390/biom11121858. PubMed PMID: 34944502; PubMed Central PMCID: PMC8699537.
 37. Grazia Martina M, Vicenti I, Bauer L, Crespan E, Rango E, Boccuto A, Olivieri N, Incerti M, Zwaagstra M, Allodi M, Bertoni S, Dreassi E, Zazzi M, van Kuppeveld FJM, Maga G, Radi M. Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIII β) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses. *ChemMedChem*. 2021 Dec 6;16(23):3548-3552. doi: 10.1002/cmdc.202100483. Epub 2021 Sep 7. PubMed PMID: 34382337; PubMed Central PMCID: PMC8427023.

38. Vicenti I, Martina MG, Boccutto A, De Angelis M, Giavarini G, Dragoni F, Marchi S, Trombetta CM, Crespan E, Maga G, Eydoux C, Decroly E, Montomoli E, Nencioni L, Zazzi M, Radi M. System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. *Eur J Med Chem.* 2021 Nov 15;224:113683. doi: 10.1016/j.ejmech.2021.113683. Epub 2021 Jul 5. PubMed PMID: 34273661; PubMed Central PMCID: PMC8255191.
39. Saladini F, Giannini A, Giammarino F, Boccutto A, Dragoni F, Vicenti I, Zazzi M. In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir. *J Antimicrob Chemother.* 2021 Nov 12;76(12):3310-3312. doi: 10.1093/jac/dkab309. PubMed PMID: 34402509.
40. Vicenti I, Basso M, Gatti F, Scaggiante R, Boccutto A, Zago D, Modolo E, Dragoni F, Parisi SG, Zazzi M. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. *Int J Infect Dis.* 2021 Nov;112:40-44. doi: 10.1016/j.ijid.2021.08.052. Epub 2021 Sep 2. PubMed PMID: 34481967; PubMed Central PMCID: PMC8410637.
41. Vicenti I, Gatti F, Scaggiante R, Boccutto A, Zago D, Basso M, Dragoni F, Parisi SG, Zazzi M. BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. *Life (Basel).* 2021 Aug 29;11(9). doi: 10.3390/life11090896. PubMed PMID: 34575045; PubMed Central PMCID: PMC8470771.
42. Lai A, Bergna A, Menzo S, Zehender G, Caucci S, Ghisetti V, Rizzo F, Maggi F, Cerutti F, Giurato G, Weisz A, Turchi C, Bruzzone B, Ceccherini Silberstein F, Clementi N, Callegaro A, Sagradi F, Francisci D, Venanzi Rullo E, Vicenti I, Clementi M, Galli M. Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021. *Virology.* 2021 Aug 14;18(1):168. doi: 10.1186/s12985-021-01638-5. PubMed PMID: 34391446; PubMed Central PMCID: PMC8364297.
43. Trombetta CM, Marchi S, Viviani S, Manenti A, Benincasa L, Ruello A, Bombardieri E, Vicenti I, Zazzi M, Montomoli E. Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. *Viruses.* 2021 Jul 12;13(7). doi: 10.3390/v13071347. PubMed PMID: 34372553; PubMed Central PMCID: PMC8310013.
44. Vicenti I, Gatti F, Scaggiante R, Boccutto A, Modolo E, Zago D, Basso M, Dragoni F, Bartolini N, Zazzi M, Parisi SG. Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection. *Open Forum Infect Dis.* 2021 Jul;8(7):ofab312. doi: 10.1093/ofid/ofab312. eCollection 2021 Jul. PubMed PMID: 34295945; PubMed Central PMCID: PMC8291533.
45. Vicenti I, Gatti F, Scaggiante R, Boccutto A, Zago D, Basso M, Dragoni F, Zazzi M, Parisi SG. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. *Int J Infect Dis.* 2021 Jul;108:176-178. doi: 10.1016/j.ijid.2021.05.033. Epub 2021 May 19. PubMed PMID: 34022329; PubMed Central PMCID: PMC8132552.
46. Manini I, Camarri A, Marchi S, Trombetta CM, Vicenti I, Dragoni F, Lazzeri G, Bova G, Montomoli E, Capecci PL. Surveillance for Severe Acute Respiratory Infections among Hospitalized Subjects from 2015/2016 to 2019/2020 Seasons in Tuscany, Italy. *Int J Environ Res Public Health.* 2021 Apr 7;18(8). doi: 10.3390/ijerph18083875. PubMed PMID: 33917106; PubMed Central PMCID: PMC8067855.
47. Vicenti I*, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. *Expert Opin Ther Pat.* 2021 Apr;31(4):325-337. doi: 10.1080/13543776.2021.1880568. Epub 2021 Mar 3. Review. PubMed PMID: 33475441; PubMed Central PMCID: PMC7938656.
48. Boccutto A, Dragoni F, Piccarazzi F, Lai A, Della Ventura C, Veo C, Giammarino F, Saladini F, Zehender G, Zazzi M, Mori M, Vicenti I*. Sofosbuvir s for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. *Int J Mol Sci.* 2021 Mar 6;22(5). doi: 10.3390/ijms22052670. PubMed PMID: 33800884; PubMed Central PMCID: PMC7962015.
49. Vicenti I*, Dragoni F, Monti M, Trombetta CM, Giannini A, Boccutto A, Saladini F, Rossetti B, De Luca A, Ciabattini A, Pastore G, Medagliani D, Orofino G, Montomoli E, Zazzi M. Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. *J Gen Virol.* 2021 Jan;102(1). doi: 10.1099/jgv.0.001499. PubMed PMID: 33048041.
50. Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccutto A, Dragoni F, Vicenti I, Shafer RW, Zazzi M. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. *J Antimicrob Chemother.* 2021 Jan 1;76(1):130-134. doi: 10.1093/jac/dkaa401. PubMed PMID: 32974670; PubMed Central PMCID: PMC8453390.
51. Piccarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. *Molecules.* 2020 Dec 3;25(23). doi: 10.3390/molecules25235695. Review. PubMed PMID: 33287144; PubMed Central PMCID: PMC7730706.
52. Vergori A, Rossetti B, Vicenti I, Meini G, Lentini G, Valoriani B, Caudai C, Morandi M, Cusi MG, Zazzi M, De Luca A. Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. *Infez Med.* 2020 Nov 1;28(4):576-586. PubMed PMID: 33257634.
53. Riva V, Garbelli A, Brai A, Casiraghi F, Fazi R, Trivisani CI, Boccutto A, Saladini F, Vicenti I, Martelli F, Zazzi M, Giannocchini S, Dreassi E, Botta M, Maga G. Unique Domain for a Unique Target: ivermectin Inhibitors of Host Cell DDX3X to Fight Emerging Viruses. *J Med Chem.* 2020 Sep 10;63(17):9876-9887. doi: 10.1021/acs.jmedchem.0c01039. Epub 2020 Aug 18. PubMed PMID: 32787106.
54. Lai A, Bergna A, Caucci S, Clementi N, Vicenti I, Dragoni F, Cattelan AM, Menzo S, Pan A, Callegaro A, Tagliabracchi A, Caruso A, Caccuri F, Ronchiadin S, Balotta C, Zazzi M, Vaccher E, Clementi M, Galli M, Zehender G. Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. *Viruses.* 2020 Jul 24;12(8). doi: 10.3390/v12080798. PubMed PMID: 32722343; PubMed Central PMCID: PMC7472216.
55. Marchi S, Viviani S, Montomoli E, Tang Y, Boccutto A, Vicenti I, Zazzi M, Sow S, Diallo A, Idoko OT, Bhat N, Trombetta CM. Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. *Viruses.* 2020 Jun 13;12(6). doi: 10.3390/v12060641. PubMed PMID: 32545775; PubMed Central PMCID: PMC7354557.
56. Vicenti I*, Dragoni F, Giannini A, Giammarino F, Spinicci M, Saladini F, Boccutto A, Zazzi M. Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. *SLAS Discov.* 2020 Jun;25(5):506-514. doi: 10.1177/2472555220911456. Epub 2020 Mar 18. PubMed PMID: 32186426.

57. Brai A, Boccuto A, Monti M, Marchi S, Vicenti I, Saladini F, Trivisani CI, Pollutri A, Trombetta CM, Montomoli E, Riva V, Garbelli A, Nola EM, Zazzi M, Maga G, Dreassi E, Botta M. Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor. *ACS Med Chem Lett.* 2020 May 14;11(5):956-962. doi: 10.1021/acsmchemlett.9b00681. eCollection 2020 May 14. PubMed PMID: 32435411; PubMed Central PMCID: PMC7236276.
58. Dragoni F, Boccuto A, Piccarazzi F, Giannini A, Giammarino F, Saladini F, Mori M, Mastrangelo E, Zazzi M, Vicenti I*. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. *Antiviral Res.* 2020 Mar;175:104708. doi: 10.1016/j.antiviral.2020.104708. Epub 2020 Jan 10. PubMed PMID: 31931104.
59. Scutari R, Alteri C, Vicenti I, Di Carlo D, Zuccaro V, Incardona F, Borghi V, Bezenchek A, Andreoni M, Antinori A, Perno CF, Cascio A, De Luca A, Zazzi M, Santoro MM. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. *J Glob Antimicrob Resist.* 2020 Mar;20:163-169. doi: 10.1016/j.jgar.2019.07.015. Epub 2019 Jul 19. PubMed PMID: 31330378.
60. Bavaro DF, Di Carlo D, Rossetti B, Bruzzone B, Vicenti I, Pontali E, Zoncada A, Lombardi F, Di Giambenedetto S, Borghi V, Pecorari M, Milini P, Meraviglia P, Monno L, Saracino A. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA. *Antivir Ther.* 2020;25(2):61-71. doi: 10.3851/IMP3349. PubMed PMID: 32118584.
61. Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, Vicenti I, Zazzi M. Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. *Antimicrob Agents Chemother.* 2019 Dec 20;64(1). doi: 10.1128/AAC.01717-19. Print 2019 Dec 20. PubMed PMID: 31611362; PubMed Central PMCID: PMC7187585.
62. Giacomelli A, Lai A, Franzetti M, Maggiolo F, Di Giambenedetto S, Borghi V, Francisci D, Magnani G, Pecorari M, Monno L, Vicenti I, Lepore L, Lombardi F, Paolucci S, Rusconi S. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. *Antiviral Res.* 2019 Dec;172:104635. doi: 10.1016/j.antiviral.2019.104635. Epub 2019 Oct 17. PubMed PMID: 31629714.
63. Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, Di Biagio A. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. *Clin Microbiol Infect.* 2019 Nov;25(11):1443-1446. doi: 10.1016/j.cmi.2019.07.004. Epub 2019 Jul 25. PubMed PMID: 31352080.
64. Alteri C, Scutari R, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. *Virus Genes.* 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22. PubMed PMID: 30796743.
65. Giannini A, Vicenti I, Materazzi A, Boccuto A, Dragoni F, Zazzi M, Saladini F. The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro. *J Antimicrob Chemother.* 2019 Mar 1;74(3):607-613. doi: 10.1093/jac/dky479. PubMed PMID: 30462235.
66. Vicenti I*, Lai A, Giannini A, Boccuto A, Dragoni F, Saladini F, Zazzi M. Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A. *J Clin Virol.* 2019 Feb;111:12-18. doi: 10.1016/j.jcv.2018.12.007. Epub 2018 Dec 19. PubMed PMID: 30594700.
67. Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. *HIV Med.* 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21. PubMed PMID: 30461149.
68. Vicenti I*, Rossetti B, Mariano S, Saladini F, Montagnani F, Zazzi M, De Luca A. Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia. *New Microbiol.* 2018 Oct;41(4):302-305. Epub 2018 Sep 25. PubMed PMID: 30252927.
69. Vicenti I*, Meini G, Saladini F, Giannini A, Boccuto A, Schiaroli E, Zazzi M. Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood. *Clin Chem Lab Med.* 2018 Feb 23;56(3):e75-e77. doi: 10.1515/ccm-2017-0587. PubMed PMID: 28915108.
70. Vicenti I*, Boccuto A, Giannini A, Dragoni F, Saladini F, Zazzi M. Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. *Virus Res.* 2018 Jan 15;244:64-70. doi: 10.1016/j.virusres.2017.11.003. Epub 2017 Nov 4. PubMed PMID: 29113824.
71. Bekele Y, Graham RL, Soeria-Atmadja S, Nasi A, Zazzi M, Vicenti I, Naver L, Nilsson A, Chiodi F. Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?. *Front Immunol.* 2017;8:1966. doi: 10.3389/fimmu.2017.01966. eCollection 2017. PubMed PMID: 29375579; PubMed Central PMCID: PMC5767726.
72. Saladini F, Giannini A, Boccuto A, Vicenti I, Zazzi M. Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors. *J Clin Lab Anal.* 2018 Jan;32(1). doi: 10.1002/jcla.22206. Epub 2017 Mar 17. PubMed PMID: 28303602; PubMed Central PMCID: PMC6816933.
73. Saladini F, Giannini A, Boccuto A, Tiezzi D, Vicenti I, Zazzi M. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro. *AIDS.* 2017 Oct 23;31(16):2307-2309. doi: 10.1097/QAD.0000000000001616. PubMed PMID: 28832412.
74. Rossotti R, Borghi V, Callegaro AP, Micheli V, Bruzzone B, Colao G, Gismondo MR, Vicenti I, Penco G, Zazzi M, Rusconi S. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. *J Clin Virol.* 2016 Oct;83:48-53. doi: 10.1016/j.jcv.2016.08.293. Epub 2016 Aug 23. PubMed PMID: 27591555.
75. Vicenti I*, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. *J Clin Virol.* 2016 Mar;76:20-3. doi: 10.1016/j.jcv.2016.01.006. Epub 2016 Jan 12. PubMed PMID: 26802683.
76. Rosi A, Meini G, Materazzi A, Vicenti I, Saladini F, Zazzi M. Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by ivermectin multiplex endpoint PCR. *J*

	<p>Virology Methods. 2015 Nov;224:102-4. doi: 10.1016/j.jviromet.2015.08.020. Epub 2015 Sep 2. PubMed PMID: 26341061.</p> <p>77. De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infect Dis</i>. 2015 Apr;2(2):ofv043. doi: 10.1093/ofid/ofv043. eCollection 2015 Apr. PubMed PMID: 26213689; PubMed Central PMCID: PMC4511743.</p> <p>78. Meini G, Balestrieri M, Cianchino S, Tacconi D, Rossi de Gasperis M, Concato C, Vicenti I, Rosi A, Saladini F, Callea F, Zazzi M. Frequent detection of antiretroviral drug resistance in HIV-1-infected orphaned children followed at a donor-funded rural pediatric clinic in Dodoma, Tanzania. <i>AIDS Res Hum Retroviruses</i>. 2015 Apr;31(4):448-51. doi: 10.1089/AID.2014.0251. Epub 2014 Dec 31. PubMed PMID: 25492218.</p> <p>79. Meini G, Materazzi A, Saladini F, Rosi A, Vicenti I, Mancini M, Pirazzoli A, Caudai C, Zazzi M. Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism. <i>BMC Infect Dis</i>. 2013 Oct 30;13:508. doi: 10.1186/1471-2334-13-508. PubMed PMID: 24172636; PubMed Central PMCID: PMC3819463.</p> <p>80. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, Di Giambenedetto S, Almi P, De Luca A, Caudai C, Zazzi M. <u>Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.</u> <i>J Antimicrob Chemother</i>. 2012 Apr;67(4):984-7. doi: 10.1093/jac/dkr581. Epub 2012 Jan 18. PubMed PMID: 22258932.</p> <p>81. Saladini F, Foley BT, Rosi A, Vicenti I, Nannetti G, Meini G, Razzolini F, Zazzi M. Near full-length sequence analysis of HIV type 1 BF recombinants from Italy. <i>AIDS Res Hum Retroviruses</i>. 2012 Mar;28(3):299-303. doi: 10.1089/aid.2011.0002. Epub 2011 Jul 8. PubMed PMID: 21740272; PubMed Central PMCID: PMC3292755.</p> <p>82. Lai A, Riva C, Marconi A, Balestrieri M, Razzolini F, Meini G, Vicenti I, Rosi A, Saladini F, Caramma I, Franzetti M, Rossini V, Galli A, Galli M, Violin M, Zazzi M, Balotta C. Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. <i>HIV Med</i>. 2010 Oct 1;11(9):593-602. doi: 10.1111/j.1468-1293.2010.00832.x. Epub 2010 Jun 28. PubMed PMID: 20408891.</p> <p>83. Saladini F, Vicenti I, Razzolini F, Zazzi M. Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy. <i>Clin Microbiol Infect</i>. 2010 Jul;16(7):848-51. doi: 10.1111/j.1469-0691.2009.03005.x. Epub 2009 Jul 21. PubMed PMID: 19681953.</p> <p>84. Balestrieri M, Marconi A, Meini G, Rosi A, Saladini F, Vicenti I, Razzolini F, Zazzi M. Impact of remote versus local sampling on sensitivity of genotypic antiretroviral resistance testing. <i>J Clin Microbiol</i>. 2010 Jun;48(6):2321-2. doi: 10.1128/JCM.02394-09. Epub 2010 Apr 21. PubMed PMID: 20410346; PubMed Central PMCID: PMC2884515.</p> <p>85. Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. <i>J Antimicrob Chemother</i>. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. PubMed PMID: 19620134.</p> <p>86. Razzolini F, Saladini F, Malincarne L, Vicenti I, Palladino N, Romano L, Francisci D, Zazzi M. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naïve heterosexual couple. <i>J Clin Microbiol</i>. 2008 Nov;46(11):3856-9. doi: 10.1128/JCM.01122-08. Epub 2008 Sep 24. PubMed PMID: 18845824; PubMed Central PMCID: PMC2576576.</p> <p>87. Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naïve HIV-infected subjects. <i>Clin Infect Dis</i>. 2007 Jun 15;44(12):1657-61. doi: 10.1086/518287. Epub 2007 May 8. PubMed PMID: 17516412.</p> <p>88. Razzolini F, Vicenti I, Saladini F, Micheli V, Romano L, Cargnel A, Zazzi M. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. <i>AIDS Res Hum Retroviruses</i>. 2007 Apr;23(4):558-63. doi: 10.1089/aid.2006.0273. PubMed PMID: 17451345.</p> <p>89. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, Duca P, Caramma I, Balotta C, Zazzi M. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. <i>Antivir Ther</i>. 2006;11(3):329-34. PubMed PMID: 16759049.</p> <p>*Corresponding author</p>
Editor and reviewing	<ul style="list-style-type: none"> Peer-review activities since 2017 for various indexed journals including <i>Antiviral Research</i>, <i>Clinical Microbiology and Infection</i>, <i>Drug Resistance Update</i>, and <i>Microbiology Spectrum</i>; <i>Lancet HIV</i>, <i>Viruses</i>, <i>Frontiers in Cellular and Infection in Microbiology</i> Guest Editor for <i>International Journal of Molecular Science</i> and <i>Viruses and Viruses</i>.

Most relevant activities as speaker in international congress or educational events

INVITED SPEAKER AND ORGANIZATION OF SCIENTIFIC CONGRESS	<ol style="list-style-type: none"> "La determinazione della sieropositività ad HIV". Educational event organized by the Azienda USL Toscana Sud Est "Le nuove frontiere dell'assistenza nella cura e prevenzione dell'AIDS", 22 November 2017, Grosseto. Invited speaker at AREVIR Meeting 03-04 May 2019, Koln, Germany. Title of report "Maraviroc as a Latency Reversing Agent in cell line models". "Diagnostica ed attività di ricerca delle infezioni da vettore". N. 15 Crediti Formativi E.C.M. Corso di formazione accreditato a livello regionale (n. 9022019062644) organizzato dall'Azienda Ospedaliera Universitaria Senese "ANTIMICROBIAL STEWARDSHIP E DIAGNOSTICA MICROBIOLOGICA: AGGIORNAMENTO SUI PERCORSI CLINICO DIAGNOSTICI IN AOUS IN AMBITO MICROBIOLOGICO", 8 July and 14 October 2019, Siena.
---	---

4. "HIV: novità nel laboratorio di virologia". Training course organized by azienda USL Toscana Sud Est "La gestione dell'infezione da HIV e nuove sfide infettivologiche", 21 February-27 March 2020, Arezzo.
5. **Member of Scientific Committee** in the 14° National Congress ICAR (Italian Conference on AIDS and Antiviral Research). Bergamo, 14-16 June 2022
6. Invited speaker at "XIV Workshop Nazionale Innovazione e Ricerca per la Pratica Clinica, TERAPIA E PREVENZIONE DELL'INFEZIONE DA HIV E MICRORGANISMI EMERGENTI". Firenze. 28 February 2022. Title of Lecture: "Origine ed evoluzione nel corso della pandemia del virus SARS-CoV-2".
7. **Invited speaker** at Webinar cycle organized by Italian Society of Microbiology (SIM). Webinar Title "The persistence of HIV-1 in latent reservoirs: one of the greatest challenges in HIV research", 16 January 2023
8. **Member of Scientific Committee** in the 15° National Congress ICAR (Italian Conference on AIDS and Antiviral Research). Bari, 14-16 June 2023
9. **Member of the Faculty and speaker** at the 7° National Congress of the Italian Society of Virology, Brescia 25-27 June 2023. Title of the presentation (OC17): "Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study."
10. **Invited speaker** at the international meeting "AREVIR-GenaFor" focusing on therapeutic optimization in HIV, HCV, and/or HBV positive patients. Congress venue: Cologne (Koln), Germany. Title of the presentation: "Study on the neutralizing antibody response to the 4th dose of the Pfizer vaccine in residents of a long-term care facility." Online presentation. 28/04/2023
11. **Member of the Faculty and invited speaker** at the "XVI National Workshop on Innovation and Research for Clinical Practice, therapy and prevention of HIV infection and emerging microorganisms," held in Florence from February 13th to 14th, 2023. Title of the lecture: "The toolkit to investigate HIV reservoir."
12. **Invited speaker** at residential Course "SIMIT NEXT GENERATION MASTER CLASS IN HIV: aspetti virologici dell'infezione da HIV" Rome 5 July 2023. Title of relation: "HIV-1 DNA, significato clinico, come valutarlo e quando valutarlo".
13. **Invited speaker** at Course "Prospettive sull'HIV, un viaggio attraverso la storia, il presente ed il futuro della lotta contro il virus" Pistoia 6 October 2023. Title of relation: "Il significato clinico dei blip viremici. Il punto di vista del virologo".
14. **Invited speaker** at the meeting "Aggiornamento sull'impiego e sull'interpretazione del test di resistenza agli antiretrovirali nella pratica clinica" Albano Laziale (Roma), 18-19 April 2024.
15. **Invited speaker** at the international meeting AREVIR, Koln, Germany 2-4 May 2024. Relation: "EuCare Immunity Study 01: neutralizing antibody response against SAR-CoV -2 in Health Care Workers. Conclusive Results".
16. **Member of the Faculty and invited speaker** at the Conference "Beyond HIV, taking HIV to another level, Beyond HIV undetectability" accredited by Italian Ministry of Health. Title of presentation: "From drug mechanisms to therapeutics and back". Milan, 15/04/2024
17. **Member of the Faculty and invited speaker** at the Expert Meeting "HIV in real life: L'evoluzione della terapia ARV" organized by Perugia Hospital and accredited by Italian Ministry of Health for ECM. Title of presentation: "Viremie di basso livello. Come gestirle? Punto di vista del virologo". Perugia, 20/05/2024
18. **Member of the Faculty** at the 16° Italian Conference of Antiretroviral Therapy, Rome (19-21 June)
19. **Member of the Faculty and invited speaker** at the "ARCA Factory 2024" formation event, Bologna, from 30-09-2024 to 1-10-2024. Relation title: "Nuove classi di farmaci e nuove mutazioni".
20. **Member of the Faculty and invited speaker** at the "XXIII CONGRESSO NAZIONALE SIMIT", Naples, 2-5 December 2024. Relation title: "Evoluzione virologica dell'infezione da SARS-CoV-2" in the symposium "NUOVI SCENARI DELL'INFEZIONE DA SARS-CoV-2".
21. **Invited speaker** at the formative event: "Persone che vivono con HIV nell'epoca delle sfide per una salute globale" organizzato nell'ambito dei corsi AIDS SIMIT Toscana". Title of intervent: "Inquadramento e gestione della Low Level Viremia". Firenze, 1 and April 2025.
22. **Member of the Faculty and invited speaker** at the 17° Congresso Nazionale ICAR 2025. Title of the relation "How to investigate HIV persistence". Padova, 22 April 2025.
23. **Member of the Faculty and invited speaker at the Specialistic seminar ECM** "From Basic Science to Clinical Practice: open issues in HIV treatment". Title of the relation: Fallimenti virologici in assenza di mutazioni di resistenza". Milano, 27 June 2025.

In fede/Signature

ROMA 14/07/2025

Ilaria Vicenti

A handwritten signature in black ink, appearing to read 'Ilaria Vicenti', is written over a faint, circular watermark or stamp.